WASHINGTON – CUBRC, a Buffalo-based research and development firm, got a big boost in the federal funding bill passed by Congress this week to end the government shutdown.
The bill contains language inserted by Sen. Charles E. Schumer, D-N.Y., that restores funding for the Biomedical Advanced Research and Development Authority, an agency whose funding had run dry.
That matters to CUBRC because the Buffalo company has a contract from the agency, worth up to $70 million over five years, to develop a new antibiotic to combat biothreats such as anthrax and plague as well as pneumonia and other infections.
“Through the federal funding bill passed last night, we can again feel confident that CUBRC can continue its lifesaving research to develop the next generation treatments for bacterial infections and biothreats,” Schumer said. “This shows plain and simple why shutting down the government was such a terrible idea that did real damage to our economy, and why it is such good news that we have moved beyond that.”
Six CUBRC employees work directly on the government contract, while another seven provide support for the project.
The company expects to receive approximately $16 million because of the language in the spending bill.